

# Jianyou Shi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2886357/publications.pdf>

Version: 2024-02-01

47  
papers

1,685  
citations

394421

19  
h-index

302126

39  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent research and development of DYRK1A inhibitors. Chinese Chemical Letters, 2022, 33, 1841-1849.	9.0	7
2	A review on the treatment of multiple myeloma with small molecular agents in the past five years. European Journal of Medicinal Chemistry, 2022, 229, 114053.	5.5	5
3	NAE modulators: A potential therapy for gastric carcinoma. European Journal of Medicinal Chemistry, 2022, 231, 114156.	5.5	5
4	Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence. Pharmacological Research, 2022, 181, 106259.	7.1	9
5	Genus <i>Spatholobus</i> : a comprehensive review on ethnopharmacology, phytochemistry, pharmacology, and toxicology. Food and Function, 2022, 13, 7448-7472.	4.6	3
6	Polysaccharide conjugate vaccine: A kind of vaccine with great development potential. Chinese Chemical Letters, 2021, 32, 1331-1340.	9.0	14
7	Angiogenic Actions of Paeoniflorin on Endothelial Progenitor Cells and in Ischemic Stroke Rat Model. The American Journal of Chinese Medicine, 2021, 49, 863-881.	3.8	11
8	Recent advances of dual FGFR inhibitors as a novel therapy for cancer. European Journal of Medicinal Chemistry, 2021, 214, 113205.	5.5	17
9	Identification of Allosteric Inhibitors of CD73 Using Three-Phrase Computational Protocol for Drug Discovery. FASEB Journal, 2021, 35, .	0.5	0
10	Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy. Frontiers in Pharmacology, 2021, 12, 702360.	3.5	15
11	Recent research and development of NDM-1 inhibitors. European Journal of Medicinal Chemistry, 2021, 223, 113667.	5.5	34
12	Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research. European Journal of Medicinal Chemistry, 2021, 226, 113842.	5.5	12
13	A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years. European Journal of Medicinal Chemistry, 2020, 186, 111852.	5.5	5
14	Recent research progress on natural small molecule bibenzyls and its derivatives in Dendrobium species. European Journal of Medicinal Chemistry, 2020, 204, 112530.	5.5	58
15	Advances of CCR5 antagonists: From small molecules to macromolecules. European Journal of Medicinal Chemistry, 2020, 208, 112819.	5.5	27
16	Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2020, 5, 213.	17.1	387
17	Advances in the Development of Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 10594-10617.	6.4	54
18	Chitosan, N,N,N-trimethyl chitosan (TMC) and 2-hydroxypropyltrimethyl ammonium chloride chitosan (HTCC): The potential immune adjuvants and nano carriers. International Journal of Biological Macromolecules, 2020, 154, 339-348.	7.5	54

#	ARTICLE	IF	CITATIONS
19	Recent researches for dual Aurora target inhibitors in antitumor field. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112498.	5.5	1
20	Structure-activity relationships of Wee1 inhibitors: A review. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112524.	5.5	19
21	Antibodies against polyethylene glycol in human blood: A literature review. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 102, 106678.	0.7	62
22	Research progress on sirtuins family members and cell senescence. <i>European Journal of Medicinal Chemistry</i> , 2020, 193, 112207.	5.5	33
23	Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7697-7707.	6.4	10
24	Antidiabetic Potential of Flavonoids from Traditional Chinese Medicine: A Review. <i>The American Journal of Chinese Medicine</i> , 2019, 47, 933-957.	3.8	120
25	Protective effect of ethyl vanillin against $A\beta^{25}$ -induced neurotoxicity in PC12 cells via the reduction of oxidative stress and apoptosis. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 2666-2674.	1.8	8
26	Recent Advances of Natural Polyphenols Activators for Keap1-Nrf2 Signaling Pathway. <i>Chemistry and Biodiversity</i> , 2019, 16, e1900400.	2.1	117
27	Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy. <i>Nanoscale Research Letters</i> , 2019, 14, 193.	5.7	33
28	Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111682.	5.5	102
29	The measured essentiality of electron effective mass on electron transport behavior and optical band gap in Ga-doped ZnO thin films. <i>Journal of Materials Science</i> , 2019, 54, 12659-12667.	3.7	2
30	Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 468-483.	5.5	27
31	&lt;p>&lt;AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma&lt;/p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4321-4330.	4.3	9
32	Polysaccharides from Chinese herbal medicine for anti-diabetes recent advances. <i>International Journal of Biological Macromolecules</i> , 2019, 121, 1240-1253.	7.5	89
33	Recent Progress on the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1051-1058.	2.1	17
34	Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1041-1050.	2.1	8
35	The protective effect of shikonin on renal tubular epithelial cell injury induced by high glucose. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 701-708.	5.6	26
36	Inhibitors of phosphodiesterase as cancer therapeutics. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 742-756.	5.5	78

#	ARTICLE	IF	CITATIONS
37	Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 1443-1456.	6.7	12
38	Assessing the performance of docking scoring function, FEP, MM-GBSA, and QM/MM-GBSA approaches on a series of PLK1 inhibitors. <i>MedChemComm</i> , 2017, 8, 1452-1458.	3.4	39
39	Recent advances in discovery and development of natural products as a source for anti-Parkinson's disease lead compounds. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 257-272.	5.5	66
40	Preparation of surface multiple-coated polylactide acid drug-loaded nanoparticles for intranasal delivery and evaluation on its brain-targeting efficiency. <i>Drug Delivery</i> , 2016, 23, 269-276.	5.7	9
41	Synthesis of New Chiral Benzimidazolylidene-Rh Complexes and Their Application in Asymmetric Addition Reactions of Organoboronic Acids to Aldehydes. <i>Catalysts</i> , 2016, 6, 132.	3.5	5
42	Synthesis and Antitumor Evaluation of Novel 5-Hydrosulfonyl-1H-benzo[d]imidazol-2(3H)-one Derivatives. <i>Molecules</i> , 2016, 21, 516.	3.8	3
43	Synthesis of C2-Symmetric Benzimidazolium Salts and Their Application in Palladium-Catalyzed Enantioselective Intramolecular $\alpha$ -Arylation of Amides. <i>Molecules</i> , 2016, 21, 742.	3.8	8
44	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 294-299.	5.5	16
45	Efficient construction of highly functionalized pyrrolo[1,2-c]imidazol-1-ones via a regioselective 1,3-dipolar cycloaddition of imidazolidin-4-ones, aldehydes, and nitroalkenes in one pot. <i>Tetrahedron Letters</i> , 2016, 57, 1143-1145.	1.4	4
46	Emerging targets and new small molecule therapies in Parkinson's disease treatment. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1419-1430.	3.0	20
47	Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4273-4278.	2.2	25